Virpax Pharmaceuticals In... (VRPX)
| Bid | 0.25 |
| Market Cap | 305.65K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.07M |
| EPS (ttm) | -71 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.02 |
| Analyst | n/a |
| Ask | 0.3 |
| Volume | 5,464 |
| Avg. Volume (20D) | 402,587 |
| Open | 0.26 |
| Previous Close | 0.29 |
| Day's Range | 0.25 - 0.27 |
| 52-Week Range | 0.14 - 84.75 |
| Beta | 1.42 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...
1 month ago · businesswire.com
Virpax's NES100 to be Presented at The Society of Toxicology by NCATSBERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
2 months ago · businesswire.com
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials ConferenceBERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
